Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systematic inflammation

World Journal of Gastroenterology

Volumn 11, Issue 48, 2005, Pages 7639-7645

  Zezos, Petros ^a   Papaioannou, Georgia ^b   Nikolaidis, Nikolaos ^a   Vasiliadis, Themistoclis ^a   Giouleme, Olga ^a   Evgenidis, Nikolaos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Coagulation; Endothelial injury; Inflammation; Inflammatory bowel disease; Ulcerative colitis; Von Willebrand factor

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; D DIMER; FIBRINOGEN; MESALAZINE; THROMBIN; TRANSACTIVATOR PROTEIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD CLOT; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REMISSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ULCERATIVE COLITIS; VASCULAR ENDOTHELIUM;

EID: 31644442688     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i48.7639     Document Type: Article

References (44)

1. Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis 2002; 8:112-128
2. Hamilton MI, Dick R, Crawford L, Thompson NP, Pounder RE, Wakefield AJ. Is proximal demarcation of ulcerative colitis determined by the territory of the inferior mesenteric artery? Lancet 1995; 345: 688-690
3. Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; 2: 1057-1062
4. Juhlin L, Krause U, Shelley WB. Endotoxin-induced microclots in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1980; 15: 311-314
5. Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M, Allison MC, Pounder RE. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992; 21: 127-133
6. Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 1995; 108: 1011-1015
7. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Heys DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastronterol 1995; 90: 220-223
8. Torkvist L, Thorlacius H, Sjoqvist U, Bohman L, Lapidus A, Flood L, Agren B, Raud J, Lofberg R. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1323-1328
9. Lee LC, Spittell JA Jr, Sauer WG, Owen CA Jr, Thompson JH Jr. Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors. Gastroenterology 1968; 54: 76-85
10. Lam A, Borda IT, Inwood MJ, Thomson S. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 1975; 68: 245-251
11. de Jong E, Porte RJ, Knot EA, Verheijen JH, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30: 188-194
12. Conlan MG, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1089-1093
13. Vecchi M, Cattaneo M, de Franchis R, Mannucci PM. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 1991; 21: 165-170
14. Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn's disease. Blood Coagul Fibrinolysis 1992; 3: 773-778
15. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840-845
16. Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987; 13: 425-433
17. Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40: 1883-1889
18. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002; 30: S220-S224
19. Mannucci PM. von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359-1362
20. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GY. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140: 777-784
21. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 5: 387-394
22. Stevens TR, James JP, Simmonds NJ, McCarthy DA, Laurenson IF, Maddison PJ, Rampton DS. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-506
23. Sawyerr AM, Smith MS, Hall A, Hudson M, Hay CR, Wakefield AJ, Brook MG, Tomura H, Pounder RE. Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of the endothelial function in inflammatory bowel disease. Dig Dis Sci 1995; 40: 793-799
24. Stevens TR, Harley SL, Groom JS, Cambridge G, Leaker B, Blake DR, Rampton DS. Anti-endothelial cell antibodies in inflammatory bowel disease. Dig Dis Sci 1993; 38: 426-432
25. Xu G, Tian KL, Liu GP, Zhong XJ, Tang SL, Sun YP. Clinical significance of plasma D-dimer and von Willebrand factor levels in patients with ulcer colitis. World J Gastroenterol 2002; 8: 575-576
26. Meucci G, Pareti F, Vecchi M, Saibeni S, Bressi C, de Franchis R. Serum von Willebrand factor levels in patients with inflammatory bowel disease are related to systemic inflammation. Scand J Gastroenterol 1999; 34: 287-290
27. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29-32
28. van der Heide H, van der Brandt-Gradel V, Tytgat GN, Endert E, Wiltink EH, Schipper ME, Dekker W. Comparison of beclomethasone diproprionate and pednisolone 21-phosphate enemas in the treatment of ulcerative colitis. J Clin Gastroenterol 1988; 10: 169-172
29. van Bodegraven AA, Schoorl M, Baak JPA, Linskens RK, Bartels PC, Tuynman HA. Hemostatic imbalance in active and quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 487-493
30. van Bodegraven AA, Schoorl M, Linskens RK, Bartels PC, Tuynman HA. Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. Eur J Gastroenterol Hepatol 2002; 14: 413-418
31. Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadell OB. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 637-643
32. Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997; 44: 90-107
33. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665
34. Thor M, Yu A, Swedenborg J. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thromb Res 2002; 105: 379-383
35. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004; 94: 508-510
36. Paisley KE, Beaman M, Tooke JE, Mohamed-Ali V, Lowe GD, Shore AC. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003; 63: 624-633
37. Hurlimann D, Enseleit F, Ruschitzka F. Rheumatoid arthritis, inflammation, and atherosclerosis. Herz 2004; 29: 760-768
38. Apetrei E, Ciobanu-Jurcut R, Rugina M, Gavrila A, Uscatescu V. C-reactive protein, prothrombotic imbalance and endothelial dysfunction in acute coronary syndromes without ST elevation. Rom J Intern Med 2004; 42: 95-102
39. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429
40. Gabay C, Kushner L. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54
41. van der Poll T, van Deventer SJ, Pasterkamp G, van Mourik JA, Buller HR, tenCate JW. Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 1992; 67: 623-626
42. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990; 75: 688-695
43. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A. Abmormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinolysis 1999; 10: 145-151
44. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87: 3662-3666